Miflonide Breezhaler (Budesonide)

Budesonide, the active ingredient in Miflonide Breezhaler, is a corticosteroid presented as an inhalation powder (dry powder inhaler) for inhalation use. It treats asthma and chronic obstructive pulmonary disease (COPD) in adults and children as prescribed, reducing airway inflammation and helping maintain lung function.

GNH USA supplies Miflonide Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Miflonide Breezhaler contains budesonide, an inhaled corticosteroid that acts on the airways to control inflammation in respiratory diseases. - Asthma: improves symptom control and reduces the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): decreases symptoms and lowers the risk of flare‑ups. - Exercise‑induced bronchoconstriction: helps prevent airway narrowing during physical activity.

Budesonide inhalation may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Oral candidiasis (thrush): fungal infection of the mouth. - Hoarseness or dysphonia: voice changes after inhalation. - Cough or throat irritation: irritation of the upper airway. - Headache: mild to moderate head discomfort. - Sore throat: irritation of the pharynx. - Upper respiratory tract infection: mild viral symptoms.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Adrenal suppression: reduced endogenous cortisol production. - Pneumonia: lower respiratory infection, especially in COPD. - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Immunosuppression: increased susceptibility to infections. - Decreased bone mineral density: risk of osteoporosis with long‑term use.

When prescribing or using Miflonide Breezhaler, consider the following safety measures. - Assess infection risk: monitor for signs of respiratory infections. - Monitor growth in children: long‑term use may affect growth velocity. - Avoid abrupt discontinuation: taper dose to prevent adrenal insufficiency. - Rinse mouth after inhalation: reduces risk of oral candidiasis. - Adjust dose in hepatic impairment: consider reduced systemic exposure. - Store at room temperature: keep in original container, protect from moisture and heat.

Budesonide may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Ketoconazole: potent CYP3A4 inhibitor that can increase systemic budesonide levels. - Ritonavir: strong CYP3A4 inhibitor, may raise exposure and risk of side effects. - Rifampicin (and other strong CYP3A4 inducers): can markedly reduce budesonide effectiveness.

Moderate Interactions (Monitor Closely): - Short‑acting beta‑agonists: may increase risk of tremor or palpitations. - Anticholinergic agents: additive anticholinergic effects may occur. - Theophylline: possible increase in plasma concentrations, requiring monitoring.